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Objective: We hypothesized that a panel of inflammatory
biomarkers (ie, fraction of exhaled nitric oxide [FENO], sputum
eosinophil count, and urinary bromotyrosine [BrTyr] level)
might predict steroid responsiveness.
Methods: The original study from which this analysis originates
comprised 2 phases: a steroid-naive phase 1 and a 28-day trial of
ICSs (phase 2) during which FENO values, sputum eosinophil
counts, and urinary BrTyr levels weremeasured. The response to
ICSs was based on clinical improvements, including a 12% or
greater increase in FEV1, a 0.5-point or greater decrease in
Asthma Control Questionnaire score, and 2 doubling dose or
greater increase in provocative concentration of adenosine
59-monophosphate causing a 20% decrease in FEV1 (PC20AMP).
Healthy control subjects were also evaluated in this study for
comparison of biomarkers with those seen in asthmatic patients.
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FENO values decreased in 82% of asthmatic patients, sputum
eosinophil counts decreased in 60%, and urinary BrTyr levels
decreased in 58%.Each of the biomarkers at the steroid-naive phase
hadutility forpredicting steroidresponsiveness,but thecombination
of high FENO values and high urinary BrTyr levels had the best
power (13.3-fold, P < .01) to predict a favorable response to ICS
therapy.However, themagnitude of thedecrease inbiomarker levels
was unrelated to the magnitude of clinical response to ICS therapy.
Conclusion: A noninvasive panel of biomarkers in steroid-naive
asthmatic patients predicts clinical responsiveness to ICS
therapy. (J Allergy Clin Immunol 2015;135:877-83.)
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Inhaled corticosteroids (ICSs) are the mainstay of treatment for
asthma. However, a considerable proportion of asthmatic patients
do not respond to ICSs based on lung function,1 other clinical out-
comes, or both. The variability in response is attributed to
different mechanisms underlying the airway inflammation.2-4
Biomarkers relevant to the underlying pathophysiologic
process, the response to treatment, or both would be useful in
personalizing care of the asthmatic patient.5
Over the last decade, fraction of exhaled nitric oxide (FENO)
values and sputum eosinophil counts have been used as bio-
markers of airway inflammation and predictors of steroid respon-
siveness. FENO values are correlated with airway eosinophilia6
and associated with airway hyperresponsiveness.7 FENO values
in healthy and asthmatic populations overlap, but FENO values
are higher in asthmatic patients compared with those in healthy
subjects.8,9 Furthermore, studies indicate that high FENO values
in asthmatic patients indicate an at-risk phenotype for exacerba-
tion and predict clinical response to ICSs or oral corticosteroids.9
Eosinophils are important effector cells in asthmatic patients,
and increased numbers in the sputum and peripheral blood are
well recognized as biomarkers of active atopic inflammation.10
Levels of eosinophilia identify clinical asthma phenotypes, such
as eosinophilic and noneosinophilic asthma.10 There is a relation-
ship between sputum eosinophil counts and exacerbation on with-
drawal of steroids.2,11 Thus measurement of sputum eosinophilia
represents a possible tool for adjusting asthma therapy to reduce
exacerbations and is related to measures of airflow obstruction
and bronchial hyperresponsiveness.12 On activation, eosinophils
undergo respiratory burst, generating high levels of reactive
oxygen species,13 eicosanoids, platelet-activating factor, and
cytokines. Eosinophil peroxidase is unique in its ability to convert877
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phate causing a 20% decrease in FEV1respiratory burst–generated hydrogen peroxide into hypobro-
mous acid, a reactive brominating oxidant that modifies protein
tyrosine residues forming urinary bromotyrosine (BrTyr).13,14
Thus BrTyr is a biochemical fingerprint of eosinophil activation,
and this highly stable product can be detected in blood and urine.
Despite many studies evaluating biomarkers in asthmatic
patients, none have specifically set out to compare the variance
of biomarkers in response to treatment or evaluated the utility of
biomarkers in combination to define treatment response pheno-
types. Several studies describe correlations between FENO values
and sputum eosinophil counts.6,7,15 However, others show that the
sensitivity and specificity of the FENO value as a predictor of
sputum eosinophilia are modest, and indeed, the relationship
between FENO values and eosinophilia appears to be independent
of asthma control.16 Furthermore, anti–IL-5 therapy decreases
sputum eosinophil counts but does not affect FENO values,
suggesting that biomarkers can provide unique information about
clinical responsiveness and mechanisms of inflammation.5,17 In
this context the combination of high urinary BrTyr levels and
FENO values were found to be associated with greater odds of
asthma, but only urinary BrTyr levels were associated with
prediction of future asthma exacerbations in both pediatric and
adult cohorts.18,19 Altogether, current data indicate that the
information provided by the biomarkers FENO, sputum
eosinophils, and urinary BrTyr is not necessarily duplicative.
They provide distinct insights into the underlying patho-
physiologic mechanisms of disease and effects of treatment but,
perhaps more importantly, might provide for biomarker-based
phenotyping of clinical responders to treatment.
The purpose of this study was to determine whether a panel of
inflammatory biomarkers (FENO values, sputum eosinophil counts,
and/or urinary BrTyr levels) might accurately predict clinical
responsiveness to ICSs. Biomarkers were measured in steroid-
naive asthmatic patients in comparisonwith those inhealthy control
subjects and again after ICS therapy. Cut points for each biomarker
and combinations of biomarkers that predict steroid responsiveness
were determined. Finally, the change in each biomarker in response
to ICS therapy was evaluated to investigate the correlation of the
steroid effect on biomarkers and clinical response.METHODS
Study population
Data and samples originated from 46 patients with stable persistent asthma
between 18 and 75 years old who were enrolled in a previously described
study.20 Forty healthy control subjectswere enrolled for comparison of baseline
values of inflammatory biomarkers. Exclusion criteria for enrollment includedrespiratory tract infection in the preceding 4 weeks, a greater than 10 pack year
smoking history or smoking in the previous 3months, use of oral prednisone in
the previous 3 months, history of life-threatening asthma, FEV1 less than 50%
of predicted value, other pulmonary disease, significant comorbidity likely to
influence the conduct of the study, pregnancy, and breast-feeding.
Study design
The original study,20 from which this secondary analysis originates,
comprised 2 phases: a steroid-naive phase (phase 1) and an inhaled steroid
phase (phase 2), an open-label trial of inhaled fluticasone (500 mg twice daily
for 28 days).
Phase 1: Steroid-naive phase. ICSs and long-acting b-agonists
were withdrawn from asthmatic patients for 28 days or until loss of control
(LOC) occurred to achieve a steroid-naive state. Individualized criteria for LOC
was based onmodification of the criteria developed by Jones et al15 and included
any one of the following criteria: (1) decrease in meanmorning peak expiratory
flow by 10% or greater, (2) decrease in 2 consecutive morning or evening peak
expiratory flows by greater than 20%, (3) increase in average daily bronchodi-
lator requirement by 4 ormorepuffs, (4) increase of 2 ormore nights in nocturnal
wakening because of asthma, or (5) experience of asthma symptoms that are
distressing/intolerable.14 At LOC or after 28 days, whichever came sooner, all
asthmatic patients underwent evaluation based on measurement of lung
function,21 bronchial hyperresponsiveness to adenosine 59-monophosphate
(AMP),22 AsthmaControl Questionnaire (ACQ) scores,23 and biomarker values
(FENO valueS,24 sputum eosinophil counts,25 and urinary BrTyr levels18,19).
Phase 2: Steroid treatment. During the steroid phase, asthmatic
patients were given 500 mg of fluticasone (Flixotide; GlaxoSmithKline, Green-
ford, United Kingdom) twice daily by means of inhalation through a spacer for a
periodof 28ormoredays, duringwhich theycompletedadailydiary.After steroid
treatment, subjects underwent evaluation by measurement of lung function,21
bronchial hyperresponsiveness to AMP,22 ACQ scores,23 and biomarker values
(FENO values,24 sputum eosinophil counts,25 and urinary BrTyr levels18,19).
Defining clinical responsiveness to ICS therapy.
Steroid clinical responsiveness was defined as 1 or more of the following:
12% or greater increase in FEV1,
26 0.5-point or greater decrease in ACQ
score,23 or 2 doubling dose or greater increase in provocative concentration
of AMP causing a 20% decrease in FEV1 (PC20AMP).
22
Study procedures
A shortened 6-item version of the ACQ, a validated questionnaire for
assessing asthma control that excluded measurement of FEV1, was used.
23,27
Each itemwas scored on a 7-point scale (0-6), and a minimal clinically impor-
tant change of 0.5 in the mean of the 6 items would justify a change in the
patient’s treatment (in the absence of undue side effects or excessive costs).23
Spirometry was performed with a rolling seal spirometer (SensorMedics,
Yorba Linda, Calif) in accordance with American Thoracic Society/European
Respiratory Society guidelines.21
Bronchial hyperresponsiveness to AMP was performed by using the
standardizedprotocol of Polosa et al.22Briefly, on each challengeday,AMPdoses
(range, 0.59-300 mg/mL) were freshly prepared. Increasing doubling concentra-
tions of AMPwere delivered through a nebulizer connected to a breath-activated
dosimeter (Morgan,Kent,UnitedKingdom) at5-minute intervals, and spirometry
was performed. PC20AMP values were determined by means of linear interpola-
tion of the dose-response curve. AMP challenges in which a 20% decrease in
FEV1 was not achieved were assigned a PC20AMP value of 1200 mg/mL.
FENO values were measured with a chemiluminescence analyzer (NiOX
MINO; Aerocrine, Stockholm, Sweden) before any forced expiratory maneu-
vers according to current guidelines at an exhaled flow rate of 50 mL/s.24
After sputum induction,28 sputum eosinophil counts were obtained by
using the standardized protocol of Fahy et al.25 Briefly, total cell differentials
were obtained by counting 400 nonsquamous cells. All cell counts were read
and confirmed by 2 trained observers. A cut point of 2% or greater was used to
define eosinophilic asthma, and a cut point of less than 2% was used to define
noneosinophilic asthma.3
BrTyr levels were assayed, as previously reported, by using stable
isotope dilution HPLC with online electrospray ionization tandem mass
TABLE I. Study population
Asthmatic patients
(steroid-naive phase)
Healthy control
subjects
Sex (F/M) 29/17 21/19
Age (y) 39.8 (2.1) 35.4 (1.7)
Height (m) 1.70 (0.01) 1.72 (0.01)
Weight (kg) 78.5 (2.5) 86.7 (4.1)
Duration of asthma (y) 22.4 (2.4) NA
On ICS at baseline (no/yes) 16/30 NA
BDP equivalent (mg) 1007.7 (93.5)
Atopy (Y/N)* 37/9 11/29
Serum IgE level (kU/mL) 451 (163) 86 (21)
Eosinophilic asthma (Y/N) 30/16
Lung function
FEV1 (L) 2.54 (0.12) 3.38 (0.12)
FEV1 (%) 76.2 (3.0) 95.0 (2.0)
FVC (L) 3.97 (0.15) 4.2 (0.2)
FVC (%) 98.5 (2.1) 97.1 (2.3)
FEV1/FVC ratio 0.66 (0.02) 0.82 (0.01)
PC20AMP (mg/mL) 143.48 (51.8) NA
Asthma questionnaire
ACQ score 1.60 (0.15) NA
Results are presented as means (SEs). Eosinophilic asthma was defined as more than
2% sputum eosinophils in the steroid-naive phase.
BDP, Beclomethasone dipropionate; F, female; FVC, forced vital capacity; M, male;
NA, not applicable.
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standard, and [13C9,
15N1]-tyrosine was included to simultaneously monitor
for potential artificial generation of analyte. Amino acids in urine were
separated over a Prodigy C18 column (150 3 2.0 mm, 5 mm; Phenomenex,
Torrance, Calif) at a flow rate of 0.2 mL/min by using a discontinuous gradient
generatedwith mobile phases comprised of 0.2% formic acid in water (solvent
A) and 0.2% formic acid in acetonitrile (solvent B). The mass spectrometer
was operated in positive ionization mode. Multiple-reaction monitoring was
used to detect unique precursor product transitions of both 79Br and 81Br iso-
topologues of each bromotyrosine (natural abundance and its isotopologues)
by using unique mass/charge ratios (m/z) for the molecular cation [MH]1
precursor and product ions as follows: [79Br]Bromotyrosine, m/z
260/214; [81Br]Bromotyrosine, m/z 262/216; [79Br,13C6]Bromotyrosine,
m/z 266/220; [81Br,13C6]Bromotyrosine, m/z 268/222; [
79Br,13C9,
15N1]
Bromotyrosine, m/z 270/223; and [81Br,13C9,
15N1]Bromotyrosine, m/z
272/225. We adjusted for differences in urinary dilution based on spot
urinary creatinine concentration, with BrTyr levels reported in BrTyr
nanograms per milligram of creatinine. Under the conditions used for the
assay, no artificial bromination was detected, and average spike and recovery
was 101% (range, 98% to 105%); assay precision of less than 7% was noted
across all concentration ranges examined.18,19
Atopy was determined by using skin prick testing and defined as at least 1
positive reaction (a weal of >2 mm) to the following allergens: cat pelt, grass
mix, and house dust mite (Hollister-Stier Laboratories, Spokane, Wash).
Whole-blood IgE levels were measured by means of fluorescent Enzyme
Immunoassay ImmunoCAP total IgE (Thermo Scientific, www.phadia.com)
by Canterbury Healthy Laboratories (Christchurch, New Zealand).*Atopy is defined by at least 1 positive reaction (wheal, >2 mm) to the following
allergens: cat pelt, grass mix, and house dust mite.
P < .05 between control subjects and asthmatic patients.Study measurements and statistical analyses
The characteristics of the study population are described as means and SEs.
The paired t test was used to compare values obtained during the steroid-naive
and steroid phases to evaluate significant changes in urinary BrTyr levels,
sputum eosinophil counts, or FENO values in response to ICS treatment. Cut
points were used to evaluate urinary BrTyr levels, sputum eosinophil counts,
and FENO values as biomarkers for ICS clinical responsiveness. At the steroid-
naive phase, cut points of sputumeosinophils of 3%orgreater29 and FENO values
of 35 ppb or greater30 were based on published data. A cut point for urinary
BrTyr of 0.45 ng/mg of creatinine was selected as that maximizing the signifi-
cance of the 2-group Wilcoxon rank sum test comparison (based on values at
the steroid-naive and steroid phases). Clinical responsiveness was defined as sig-
nificant improvements in ACQ, FEV1, and PC20AMPvalues based on cut points
obtained from international guidelines. A comparison of clinical responsiveness
between subjects defined by the biomarker cut points was made by using the
Wilcoxon rank sum test. To further describe the relationships observed in the
2-group comparisons (2 groups: lower or higher than the biomarker’s cut point),
each clinical responsiveness outcome was assessed with respect to a threshold
value, yielding a dichotomous formof the outcome.Logistic regression analyses
were then used for each biomarker to estimate the odds ratio (OR) for the asso-
ciation between the biomarker level and the likelihood of achieving a clinical
response at or greater than the threshold level. Receiver operating characteristic
curves and their corresponding areas under the curve (AUCs) described visually
the relationships between dichotomized forms of responsiveness with respect to
thresholds of 1, 2, and/or 3 clinical outcomes and the continuous versions of
urinary BrTyr levels, sputum eosinophil counts, and FENO values.
Ethical considerations and patient safety
Ethics approval was obtained from the Lower South Regional Ethics
Committee of New Zealand (LRS/06/11/056, LRS/06/12/059).20RESULTS
Subjects’ characteristics
This study included a subset of 46 asthmatic patients from a
prior cohort who had completed the steroid withdrawal and
steroid phases (ICS treatment). In addition, healthy controlsubjects were studied. Baseline characteristics are shown in
Table I. In this cohort 80.4% of the asthmatic patients had atopic
asthma (Table I), and 65.2% were classified as having
eosinophilic asthma (Table I and see Table E1 in this article’s
Online Repository at www.jacionline.org). Age, sex, weight,
and height were not significantly different between control
subjects and asthmatic patients (Table I).
Effect of ICSs on inflammatory biomarkers
UrinaryBrTyr levels, FENO values, and sputumeosinophil counts
were measured at the steroid-naive and steroid phases. The inflam-
matory biomarkers (urinary BrTyr and FENO) were significantly
higher in all steroid-naive asthmatic patients compared with those
in control subjects (P < .05 for all comparisons, Table II). The
asthmatic patients had variable changes in biomarker levels with
ICS treatment: 82% of the asthmatic patients had decreased FENO
values, 60% had decreased sputum eosinophil counts, and 58%
had decreased urinary BrTyr levels after ICS therapy. The
asthmatic patients whose biomarker values did not decrease had
baseline FENO values and urinary BrTyr levels greater than those
seen in healthy control subjects, indicating that the lack of decrease
in biomarkers was not due to having ‘‘normal’’ levels.
The changes in biomarkers in asthmatic patients treated with
ICSs were not concordant (Fig 1). More than 50% of asthmatic
patients had decreases in both FENO values and sputum eosinophil
counts, but 30% of asthmatic patients had a significant decrease in
FENO values but no change in sputum eosinophil counts (Fig 1, A).
There was less concordance between FENO values and urinary
BrTyr levels, but most asthmatic patients had decreases in one
of the 2 of these biomarkers with ICS therapy (ie, only 3.8%
did not have decreased in either FENO values or urinary BrTyr
levels; Fig 1, B). Urinary BrTyr levels and sputum eosinophil
counts had the least concordant change (Fig 1, C).
TABLE II. Measurements of FENO values, sputum eosinophil counts, and urinary BrTyr levels in steroid-naive and steroid-treated
asthmatic patients and control subjects
Control
subjects
All asthmatic patients
Asthmatic patients with decreases
in biomarker values
Asthmatic patients with no
decrease in biomarker values
Steroid
naive
Steroid
treatment
Paired
t test
Steroid
naive
Steroid
treatment
Paired
t test
Responder
(%)
Steroid
naive
Steroid
treatment
Paired
t test
FENO value (ppb) 15.5 (1.1) 56.5 (5.6)* 25.8 (2.3) <.0001 61.9 (6.5)* 22.7 (1.7) <.0001 82 29.9 (7.2)* 39.8 (9.5) .03
BrTyr level (ng/mg
of creatinine)
0.28 (0.04) 0.53 (0.1)* 0.49 (0.06) .43 0.63 (0.2)* 0.45 (0.1) .006 58 0.44 (0.1)* 0.56 (0.07) .006
Eosinophil count (%) NA 18.9 (3.3) 9.9 (2.6) .012 26.5 (4.6) 9.0 (2.7) <.0001 60 4.8 (2.2) 12.8 (4.9) .08
Results are presented as means (SEs).
NA, Not applicable.
*P < .05 for all comparisons with healthy control subjects, including steroid-naive and steroid-treated patients with or without a decrease in biomarker values.
FIG 1. Changes in biomarker values in asthmatic patients treated with ICSs. The percentage of asthmatic
patients with decreases in biomarker values with ICS treatment for 28 days is shown proportionately by the
size of the colored circles (blue, FENO values; green, sputum eosinophil counts [EOS]; and red, urinary BrTyr
levels), and the percentage of asthmatic patients who do not have decreases in values of either of the 2 bio-
markers in each panel is shown by black circles.
FIG 2. Receiver operating characteristic analysis describes the ability of
each biomarker (ie, FENO values, sputum eosinophil counts, and urinary
BrTyr levels) to classify asthmatic patients who respond to ICS therapy,
as measured by 2 of 3 clinical outcomes (>_12% increase in FEV1 and/or
>_0.5-point decrease in ACQ score and/or >_2 doubling dose increase in
PC20AMP value).
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Receiver operating characteristic curve analyses were used to
assess the utility of biomarker measurements during the steroid-
naive phase for the prediction of clinical responsiveness to
steroid. Clinical responsiveness was defined as improvements in
clinical outcomes (>_12% increase in FEV1 and/or >_0.5-point
decrease in ACQ score and/or >_2 doubling dose increase in
PC20AMP value). Fig 2 shows the receiver operating character-
istic curves for FENO values, sputum eosinophil counts, and uri-
nary BrTyr levels as predictors of steroid response based on
improvement in at least 2 of the 3 clinical outcomes. Furthermore,
likelihood ratio tests confirmed that clinical responsiveness to ste-
roid was associated with FENO values (P 5 .004, Wilcoxon test),
sputum eosinophil counts (P5 .001, Wilcoxon test), and urinary
BrTyr levels (P5 .03, Wilcoxon test). The ORs for dichotomized
steroid responsiveness with improvement in 2 or 3 clinical out-
comes with respect to baseline sputum eosinophil counts of 3%
or greater were 9.20 (improvement in 2 clinical outcomes: 95%
CI, 2.31-43.09; P 5 .001) and 10.50 (improvement in 3 clinical
outcomes: 95% CI, 1.73-203.7; P 5 .002), respectively. Asth-
matic patients with baseline FENO values of 35 ppm or greater
had 10.5-fold greater likelihood of response to inhaled steroids,
as measured by improvement in at least 3 clinical outcomes
(2 clinical improvements: OR, 3.43; 95% CI, 0.93-413.54;
P 5 .004; 3 clinical outcomes: OR, 10.50; 95% CI, 1.73-203.7;
P5 .014). The ORs with respect to a baseline urinary BrTyr level
of 0.45 ng/mg of creatinine or greater were 6.22 (improvement in
2 clinical outcomes: 95% CI, 1.22-47.94; P 5 .031) and
1.5 (improvement in 3 clinical outcomes: 95% CI, 0.3-7.3;P5 .619), respectively. Asthmatic patients with high FENO values
(>_35 ppm) and high urinary BrTyr levels (>_0.45 ng/mg of creati-
nine) were 13 times as likely to have a positive response to steroid
treatment, as measured by 2 clinical outcomes (2 clinical out-
comes: OR, 13.3; 95% CI, 2.1-130.6; P 5 .007; 3 clinical out-
comes: OR, 7.2; 95% CI, 0.9-153.5; P 5 .076; Fig 3).
FIG 3. ORs and 95% CIs for the association between a high biomarker value
(FENO value, >_35 ppm; sputum eosinophil count, >_3%; and urinary BrTyr
level, >_0.45 ng/mg of creatinine) or biomarker combination (FENO and uri-
nary BrTyr) and 2 positive clinical outcomes in response to ICS therapy. Re-
sults shown represent the ORs (solid circles) and 95% CIs (lines) of having a
steroid response versus having no steroid response. Asterisks indicate a P
value of less than .05, as determined by using the likelihood ratio x2 test.
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attributed to a biomarker inflammation pathway, we evaluated the
numbers of asthmatic patients within subgroups defined by levels
greater than the cut points that are clinically relevant to each steroid
response and who also experienced a decrease in biomarker levels.
Interestingly, 90% of the steroid-naive asthmatic patients with FENO
valuesof35ppmorgreater haddecreasedFENOvalues after ICS ther-
apy, 85% with sputum eosinophils of 3% or greater had decreased
sputum eosinophil counts after ICS therapy, and 59% with urinary
BrTyr levels of 0.45 ng/mg of creatinine or greater had decreased
urinary BrTyr levels after ICS therapy. Although the majority of
asthmatic patients experience a decrease in biomarker levels, there
was no association between the magnitude of decrease in biomarker
levels and the magnitude of clinical response. However, the study
might be underpowered to detect this typeof association, and a larger
study may confirm such an association.
DISCUSSION
This is the first study to compare the utility of a panel of
biomarkers that identify the presence of atopic inflammation and
oxidative stress for prediction of clinical response to steroids. The
effect of ICSs on inflammatory biomarkers (ie, sputum eosinophil
counts, FENO values, and urinary BrTyr levels) was not uniformly
concordant, although there were substantial parallel decreases
among biomarkers. Each of the biomarkers had utility for predict-
ing steroid responsiveness; the combination of high FENO values
and high urinary BrTyr levels had particular power to predict a
favorable clinical response to ICS therapy with either improve-
ment in ACQ score, FEV1, or airway reactivity.
This study allows direct comparison among biomarkers in
response to ICS treatment. The majority of asthmatic patients
experienced a decrease in FENO values with ICS therapy, and this
was by far the most consistent biomarker to decrease compared
with either sputum eosinophil counts or urinary BrTyr levels.
FENO values are traditionally considered a surrogate marker of
eosinophilic asthma.6 Likewise, the end products of protein bromi-
nation, such as BrTyr, are considered to reflect eosinophil activa-
tion.13,14 The concept that the eosinophil plays a role in asthma
is long established, as is the clinical benefit of corticosteroids inpatients with eosinophilic asthma in association with suppression
of eosinophilic inflammation.10,31 Treatment strategies based on
sputum eosinophil counts lead to decreases in exacerbations
without increased treatment, at least in adults.2,32,33 Despite the
fact that these biomarkers provide information on atopic inflam-
mation, there was only partial concordance in response to ICSs
of the 3 inflammatory biomarkers in this study. This might be
related to the fact that FENO values correlate with bronchial
mucosal eosinophilia rather than luminal (sputum) eosinophilia.34
Epithelial inducible nitric oxide synthase has been shown to be the
main determinant of FENO,35 and it is postulated that the decrease in
FENO values seen after steroid treatment might be due to an inhib-
itory effect of steroids on inducible nitric oxide synthase induction,
perhaps irrespective of airway eosinophilia. Atopy might be an
important contributor to FENO values independent of eosinophils,
so that FENO values might remain increased in atopic subjects
despite steroid suppression of eosinophilic airway inflammation.26
Finally, FENO measurement does not allow an estimate of alveolar
and airway contributions,36 such that localization of this inflamma-
tory signal within the lower respiratory tract is not possible. Other
studies suggest discordance between biomarkers. Notably, the
administration of mepolizumab in patients with refractory eosino-
philic asthma led to a decrease in sputum eosinophil counts but no
change in FENO values.17 A study in children foundmarked discor-
dance in the longitudinal relationship between sputum eosinophil
counts and FENO values.37 Finally, in another study no correlation
was found between urinary BrTyr levels and FENO values.19 There-
fore it is possible that sputum eosinophil counts, FENO values, and
urinary BrTyr levels are not as closely linked as previously thought
and that they might represent biomarkers of different underlying
pathophysiologic mechanisms.
Sputum eosinophil counts have utility in the prediction of steroid
response2,6,29,38,39 and LOC2,40 and in titrating the steroid dose to
minimize exacerbations.33 However, sputum induction is unpleas-
ant for the patient, sputum processing and cell analysis is a time-
consuming procedure requiring technical expertise, and the test
is not widely available. Furthermore, the performance characteris-
tics of sputum eosinophil counts for the prediction of steroid
responsiveness are modest. Combining sputum eosinophil counts
and FENO values might improve this prediction. In this study the
finding of high sputum eosinophil counts was a good predictor of
steroid responsiveness, irrespective ofwhether defined by improve-
ment in 2 (AUC, 0.848) or 3 (AUC, 0.749) clinical outcomes. Both
sputum eosinophil counts and FENO values individually, but not uri-
nary BrTyr levels, had AUCs of greater than 0.7, indicating clini-
cally significant utility in prediction of steroid responsiveness,
irrespective of whether defined by improvement in 2 or 3 clinical
outcomes. Previously, we have shown that the urinary BrTyr level,
a noninvasive marker of oxidant stress and eosinophil activation, is
increased in asthmatic patients and predicts exacerbation in both
pediatric and adult asthma populations.18,19 The combination of
high FENO values and urinary BrTyr levels was associated with
the greatest likelihood of clinical response to ICS therapy. This sug-
gests that these 2 biomarkers used in combination might have su-
perior clinical utility in the prediction of steroid responsiveness,
thus avoiding the need for sputum induction, processing, and anal-
ysis and the associated discomfort for the patient.
A limitation of this study is that the ICS trial was not placebo
controlled. This was for reasons of safety. Seventy percent of
participants demonstrated LOC within 28 days after steroid
withdrawal. It would have been unethical to allow these subjects
J ALLERGY CLIN IMMUNOL
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placebo treatment. As a consequence, we conclude that some of
the changes seen in association with steroid treatment might be
explained to some degree by regression to the mean. In particular,
we cannot exclude the possibility that changes seen in sputum
eosinophil counts did not reflect regression to the mean or
variation with time, although the latter in particular seems
unlikely given the reproducibility of sputum cell measurements
over time.41 In addition, we were unable to assess the predictive
power of biomarkers for other important outcomes, such as risk
of exacerbations. Previous studies suggest that sputum eosinophil
counts,42 FENO values,9 and, at least in children, urinary BrTyr
levels19 might have a role in assessing the risk of exacerbation
in asthmatic patients. Finally, although the majority of asthmatic
patients experienced a decrease in biomarker levels, there was no
association between the magnitude of decrease in biomarker
values and magnitude of clinical response. However, the study
might be underpowered to detect this type of association, and a
larger study could confirm such an association. Future studies
will focus on evaluation of biomarker panels for assessment of
exacerbation risk and whether the magnitude of change in
biomarker values might predict the magnitude of clinical benefit
with treatments.
Key messages
d Asthmatic patients have variable and nonconcordant de-
creases in sputum eosinophil counts, FENO values, and uri-
nary BrTyr levels in response to ICS therapy.
d Each biomarker at baseline was predictive of clinical ste-
roid responsiveness, but the combination of high FENO
values and high urinary BrTyr levels had the greatest po-
wer to predict a favorable response to ICSs.
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TABLE E1. Baseline characteristics at the end of the steroid-
naive phase for all patients who completed the steroid phase
based on eosinophilic asthma
Eosinophilic
asthma (n 5 30)
Noneosinophilic
asthma (n 5 15)
Sex (F/M) 18/12 11/4
Age (y) 41.3 (2.4) 37.8 (3.9)
Height (m) 1.69 (0.01) 1.71 (0.02)
Weight (kg) 78.5 (3.0) 78.9 (4.6)
Duration of asthma (y) 23.8 (2.9) 19.7 (4.4)
On ICS at baseline (no/yes) 6/24 5/10 ACQ*
BDP equivalent (mg) 783.3 (113.6) 313.3 (147.6)*
Atopy (no/yes)* 7/24 4/11
Serum IgE level (kU/mL) 516.2 (229.9) 322.5 (133.8)
Lung function
FEV1 (L) 2.37 (0.14) 2.87 (0.21)*
FEV1 (%) 72.1 (3.4) 85.0 (5.2)*
FVC (L) 3.98 (0.21) 3.93 (0.21)
FVC (%) 100.3 (2.5) 95.1 (3.8)
FEV1/FVC ratio 0.63 (0.02) 0.72 (0.02)*
PC20AMP (mg/mL) 75.1 (46.9) 270.6 (114.9)
Asthma questionnaire
ACQ score 1.82 (0.18) 1.02 (0.17)*
Urinary BrTyr (ng/mg of
creatinine)
0.60 (1.2) 0.43 (0.06)
FENO 65.0 (7.5) 38.1 (6.0)*
Sputum eosinophil (%) 28.1 (3.9) 0.6 (0.2)*
BDP, Beclomethasone dipropionate; F, female; FVC, forced vital capacity; M, male.
*Atopy is defined by at least 1 positive reaction (wheal, >2 mm) to the following
allergens: cat pelt, grass mix, and house dust mite. P < .05 between control subjects
and asthmatic patients.
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